Sunitinib monotherapy in a patient with primary breast cancer

Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved for use in patients with advanced renal cell carcinoma (RCC). However, despite its preclinical biological effect on breast cancer, it is yet to be proven effective for clinical use in patients with breast cancer. The present repo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International cancer conference journal 2014-04, Vol.3 (2), p.91-95
Hauptverfasser:	Sumiyoshi, Hitomi, Aruga, Tomoyuki, Miyamoto, Hiromi, Ishiguro, Junko, Honda, Yayoi, Shigekawa, Takashi, Kitagawa, Dai, Horiguchi, Kazumi, Yamashita, Toshinari, Horiguchi, Shinichiro, Kuroi, Katsumasa
Format:	Artikel
Sprache:	eng
Schlagworte:	Autopsies Biopsy Breast cancer Breast carcinoma Cancer therapies Case Report Chemotherapy Estrogens Inhibitor drugs Kidney cancer Kinases Mammography Medical prognosis Medicine Medicine & Public Health Metastasis Oncology Patients Renal cell carcinoma Surgical Oncology Targeted cancer therapy Tomography Tumors Ultrasonic imaging Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!